CompletedNot Applicable

TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

United States82 participantsStarted 2017-10-03

Plain-language summary

A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients treated for femoropopliteal de novo/restenotic lesions or in-stent restenosis using Turbo Power laser atherectomy plus drug coated balloon angioplasty Exclusion Criteria: * Any incomplete data on procedural approach and treatment

What they're measuring

Number of Participants Free From Target Lesion Revascularization (TLR)

Timeframe: 1 year

Trial details

NCT IDNCT03306199

SponsorSpectranetics Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-06-05

Results submitted2018-11-20

View on ClinicalTrials.gov More Peripheral Arterial Disease trials